idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a progressive, fatal fibrotic lung disease with a median survival of 3–5 years from diagnosis. Pirfenidone and nintedanib slow disease progression but do not halt or reverse fibrosis. Combination approaches, antifibrotic agents targeting novel pathways, and early detection through risk models are the leading research priorities.